Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report)’s stock price rose 13.1% during mid-day trading on Friday . The stock traded as high as $2.1550 and last traded at $2.1550. Approximately 100 shares changed hands during trading, a decline of 13% from the average daily volume of 116 shares. The stock had previously closed at $1.9050.
Innate Pharma Price Performance
The firm has a fifty day simple moving average of $2.00 and a 200 day simple moving average of $1.84.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Read More
- Five stocks we like better than Innate Pharma
- Overbought Stocks Explained: Should You Trade Them?
- These 3 Banks Are Rallying Into Year-End, But Will It Continue?
- Growth Stocks: What They Are, What They Are Not
- 3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- This ETF Caught a Major Tailwind After the Fed’s Rate Cut
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
